Capacity Bio is developing the most comprehensive and advanced mitophagy therapeutics and development platform for the purpose of restoring mitochondria quality control in disease.
Market:
Their lead focus is neurodegeneration and muscular disorders, including Parkinson's, ALS, and DMD which targets multibillion opportunities.Technology:
Capacity Bio has a unique set of drugs that improve mitochondrial quality control by targeting receptors on the cell surface.Advantages:
- Engage target quickly and efficiently
- No need to enter cell or mitochondria
- Safe and effective
Development Stage:
- Pre-Clinical
Patents Issued:
- Coming Soon
Select Publications:
- Coming Soon
Contact:
Email: awang@capacitybio.comPhone: 310-880-6414
Website: www.capacitybio.com
Portfolio Companies
- Active Membranes, LLC.
- Avesta76 Therapeutics
- Capacity Bio
- CDR3 Therapeutics, Inc.
- Dalton Bioanalytics
- EarlyDx
- Forcyte Biotechnologies
- Gradient Orthodontics
- ImmunoVec
- Lactation Lab
- Lookin, Inc.
- Nanoarmor, LLC.
- Partillion Bioscience Corporation
- Pelage Pharmaceuticals
- Pluto Immunotherapeutics
- Scarless Laboratories
- Sorriso Pharmaceuticals
- Symphony Biosciences
- Vault Pharma
- ViBo Health
- Westwood Bioscience